Autologous Cell Therapy Market Report 2022: Reduced Risk Compared to Traditional Therapies Drives Adoption – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Autologous Cell Therapy Market Size, Share & Trends Analysis Report By Source (Bone Marrow, Mesenchymal Stem Cells), By Application (Cancer, Neurodegenerative Disorders), By End-use, By Region, And Segment Forecasts, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering.

The global autologous cell therapy market size is expected to reach USD 24.31 billion by 2030. The market is expected to expand at a CAGR of 19.4% from 2022 to 2030. The growing burden of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, and orthopedics are the factors driving the demand for the market.

Likewise, the reduced risk of autologous cell therapy rejection is one of the important factors for market growth as these therapies are developed from patient-derived cells and support the regeneration of the damaged tissues in the body.

In April 2020, Hope Biosciences, a clinical-stage biotechnology company announced the FDA clearance for a phase II clinical trial evaluating the efficacy & safety of HB-adMSCs (Hope Bioscience’ autologous, adipose-derived mesenchymal stem cells), to offer immune support against COVID-19. In June 2020, Chiesi Group and Holostem Terapie Avanzate mentioned the agreement for the transfer of the business branch Holoclar. The Holoclar is an autologous stem cell therapy for patients with ocular surface burns. It aims to allow both companies to focus on the strategic objective and accelerate procedures access for rare diseases.

Autologous Cell Therapy Market Report Highlights

• Based on sources, the bone marrow segment held the majority of the market share of around 42% in 2021 attributed to its benefits over a donor’s stem cells to treat different diseases as these cells are taken from the patient itself
• Based on application, the cancer segment dominated the market in terms of revenue share in 2021 and is also expected to witness the fastest growth at a CAGR of 20.7%. Autologous cell therapy has proven beneficial for better management of cancer. For instance, Catalent Company mentioned the first two CAR-Ts joined in 2020 by a third autologous cell therapy Tecartus (brexucabtagene autoleucel) for relapsed/refractory mantle cell lymphoma treatment
• Based on end use, the hospitals & clinics segment accounted for the largest market share of around 45% in 2021 owing to increasing patient inflow in hospitals for treatments of diseases. The TCT program (Transplantation and Cellular Therapy) at the Ottawa Hospital was the first program outside the U.S. This program has received accreditation from the Foundation for the accreditation of cellular therapy (FACT)
• In 2021, North America dominated the market in terms of revenue with a share of around 41% due to the factors such as potential advantages of autologous cell therapy over conventional therapies, rising government support, meeting regulatory requirements for manufacturing, growing burden of cancer cases has uplifted the market

Key Topics Covered:

Chapter 1 Report Scope and Objectives

Chapter 2 Methodology

Chapter 3 Executive Summary

Chapter 4 Market Variables, Trends & Scope

Chapter 5 Autologous Cell Therapy Market: Source Analysis

5.1 Autologous Cell Therapy Market Share Analysis, 2021 & 2030

5.2 Autologous Cell Therapy Market: Segment Dashboard:

5.3 Market Size & Forecasts And Trend Analyses, 2017 To 2030 For The Services Segment

5.3.1 Bone Marrow

5.3.2 Epidermis

5.3.3 Mesenchymal Stem Cells

5.3.4 Haematopoietic Stem Cells

5.3.5 Chondrocytes

5.3.6 Others

Chapter 6 Autologous Cell Therapy Market: Application Analysis

6.1 Autologous Cell Therapy Application Market Share Analysis, 2021 & 2030

6.2 Autologous Cell Therapy Application Market: Segment Dashboard:

6.3 Market Size & Forecasts And Trend Analyses, 2017 To 2030 For The Application Segment

6.3.1 Cancer

6.3.2 Neurodegenerative Disorders

6.3.3 Cardiovascular Disorders

6.3.4 Autoimmune Disorders

6.3.5 Orthopedics

6.3.6 Wound Healing

6.3.7 Others

Chapter 7 Autologous Cell Therapy Market: End-Use Analysis

7.1 Autologous Cell Therapy End-Use Market Share Analysis, 2021 & 2030

7.2 Autologous Cell Therapy End-Use Market: Segment Dashboard:

7.3 Market Size & Forecasts And Trend Analyses, 2017 To 2030 For The End-Use Segment

7.3.1 Hospitals & Clinics

7.3.2 Ambulatory Centers

7.3.3 Academics & Research

7.3.4 Others

Chapter 8 Autologous Cell Therapy Market: Regional Analysis

Chapter 9 Competitive Analysis

Companies Mentioned

• BRAINSTORM CELL THERAPEUTICS INC.
• HOLOSTEM TERAPIE AVANZATE S.R.L
• PHARMICELL CO. INC
• OPEXA THERAPEUTICS
• LISATA THERAPEUTIC (CALADRIUS BIOSCIENCES INC)
• U.S. STEM CELL INC
• LONZA
• BRISTOL MYERS SQUIBB
• NOVARTIS
• AUTOLUS THERAPEUTICS
• TEGO SCIENCE
• CORNING INCORPORATED
• BIO ELPIDA
• VERICEL CORPORATION
• CATALENT, INC
• SARTORIUS AG

   

   

For more information about this report visit https://www.researchandmarkets.com/r/ttuhsu-cell?w=4

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900